Back to Blog

Brain Injury Awareness Month in Canada

Every year, countless lives are forever changed by traumatic brain injuries (TBIs). These injuries can occur suddenly, affecting people of all ages and backgrounds. In Canada, the month of June is dedicated to raising awareness about brain injuries and the impact they have on individuals, families, and communities. Brain Injury Awareness Month serves as a reminder of the need for education, support, and prevention strategies to mitigate the devastating consequences of these injuries.

Brain injuries are complex and debilitating conditions that can have a profound impact on a person’s physical, cognitive, and emotional well-being. TBIs have a wide range of causes, including motor vehicle accidents, falls, sports-related injuries, workplace accidents, and assaults.

The challenges can interfere with one’s ability to function in daily life, in relationships, at work, or in social situations. The burden extends beyond the individual to their loved ones who support and care for them. Both the survivor and their family members may experience greater stress and isolation as a result of the significant physical, mental, and financial toll.

The Potential of Medicinal Cannabis in Brain Injury Recovery

Pain, insomnia, and anxiety are three interrelated symptoms of brain injuries known as the “pain triad,” and medicinal cannabis could treat all three symptoms simultaneously without the negative side effects associated with some medications.

Often, a combination of CBD and THC is needed to manage the symptoms; during the day, CBD has anti-inflammatory and anxiety-relieving properties without intoxication, and at bedtime, a low dose of THC eases pain and promotes sleep.

1.     Neuroprotective properties: Preclinical studies have suggested that cannabinoids, particularly CBD, possess neuroprotective properties, which means they may help protect brain cells from further damage and promote their survival.

2.     Anti-inflammatory effects: Brain injuries often lead to inflammation, which can exacerbate the damage and hinder the recovery process and can unfortunately sometimes lead to certain types of Alzheimer’s. Cannabinoids have demonstrated anti-inflammatory effects, potentially reducing neuroinflammation and facilitating the healing process.

3.     Pain management: Chronic pain is a common symptom associated with brain injuries. Medicinal cannabis has been widely acknowledged for its pain-relieving properties and has shown promise in managing various conditions, including neuropathic pain often experienced by individuals with brain injuries.

4.     Emotional stress management: Many individuals with brain injuries experience mental health concerns such as depression, anxiety, and irritability. Some studies suggest that certain cannabinoids, notably THC and CBD, may provide potential relief for these symptoms.

5.     Sleep aid: Brain injuries can disrupt the normal sleep-wake cycle, leading to various sleep disturbances. Cannabinoids (such as CBD, THC and CBN) may have both sleep-promoting and wakefulness-inducing properties.

Did you know that many Canadian insurance providers cover the use of medicinal cannabis to treat chronic neuropathic pain? Visit our Guide to Medical Cannabis Reimbursement.

While the potential for medicinal cannabis in brain injury recovery is an exciting area of research, more scientific evidence is needed to establish effectiveness, safety, and optimal utilization. Individuals considering medicinal cannabis as a supplementary therapy should consult with their healthcare provider.

Need help getting a medicinal cannabis treatment plan for a brain injury? Book an appointment here.


References:
Aychman, M. M., Goldman, D. L., & Kaplan, J. S. (2023). Cannabidiol’s neuroprotective properties and potential treatment of traumatic brain injuries. Frontiers in Neurology, 14. Retrieved from https://www.frontiersin.org/articles/10.3389/fneur.2023.1087011/full
Lins, B.R., Anyaegbu, C.C., Hellewell, S.C., Papini, M., McGonigle, T., et al. (2023). Cannabinoids in traumatic brain injury and related neuropathologies: preclinical and clinical research on endogenous, plant-derived, and synthetic compounds. Journal of Inflammation, 20, 77, 1-21. Retrieved from https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-023-02734-9#:~:text=Cannabinoids%20interact%20with%20neurons%2C%20microglia,management%20of%20traumatic%20brain%20injury.
Mechoulam, R. (2002). Cannabinoids and brain injury: therapeutic implications. Trends in Molecular Medicine, 8(2), 58–61. https://doi.org/10.1016/s1471-4914(02)02276-1
Schurman, L.D., & Lichtman, A.H. (2017). Endocannabinoids: a promising impact for traumatic brain injury. Frontiers in Pharmacology, 8, 69. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314139/pdf/fphar-08-00069.pdf.
Scuderi, C., Steardo, L., & Esposito, G. (2013). Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+Cells Through PPARγ Involvement. Phytotherapy Research, 28(7), 1007–1013. https://doi.org/10.1002/ptr.5095

Previous Article
Medical Cannabis and Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). MS occurs when the immune system attacks the myelin sheath, which is a protective covering around nerve fibers. This leads to nerve damage, which can cause a range of symptoms, including muscle weakness, spasticity, fatigue, and chronic pain. While there is no cure for MS, there are various treatments available that can help manage symptoms and slow the progression of the disease. One such treatment that has gained attention in recent years is medicinal cannabis. Medicinal cannabis has been shown to be effective in treating a range of symptoms associated with MS. One of the most significant symptoms of MS is spasticity, which refers to involuntary muscle contractions that can cause stiffness, spasms, and pain. Medicinal cannabis has been found to be effective in reducing spasticity, which can improve mobility and quality of life for MS patients. In addition to spasticity, medicinal cannabis has also been found to be effective in reducing chronic pain associated with MS. Chronic pain can be debilitating and can impact a person's ability to carry out daily activities. Medicinal cannabis can help reduce pain and improve overall quality of life for MS patients. Medicinal cannabis may also be beneficial in reducing fatigue, which is a common symptom of MS. Cannabis can have a stimulating effect that can help increase energy levels and improve mental clarity. This can help MS patients manage fatigue and carry out daily activities. Sativex is an oral spray formulation of THC and CBD that has been approved by Health Canada and is used to treat conditions like MS and cancer-related pain. It has been approved as an adjuvant therapy for adult MS patients with spasticity who have not responded well to previous treatments. When used together, THC and CBD have been found to have a synergistic effect, meaning that they work better together than they do separately. Did you know that many Canadian insurance providers offer coverage for medicinal cannabis? Visit our Guide to Medical Cannabis Reimbursement. While medicinal cannabis may be effective in treating symptoms associated with MS, it is important to note that it is not a cure for the disease. MS is a complex condition, and there is no single treatment that can address all its symptoms. Medicinal cannabis should be use in conjunction with other treatments, such as disease-modifying therapies and physical therapies, to manage symptoms and slow the progression of the disease. Medicinal cannabis is not without risks and side effects, and it is important to speak with a health care provider before using it as a treatment for MS. Cannabis can have psychoactive effects, and it may interact with other medications. Need help getting a medicinal cannabis treatment pan for multiple sclerosis? Book an appointment here. References Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000 03/02;404(0028-0836; 0028-0836; 6773):84-7.   Centonze D, Rossi S, Finazzi-Agro A, Bernardi G, Maccarrone M. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. Int Rev Neurobiol 2007;82(0074-7742; 0074-7742):171-86.   Di Filippo M, Pini LA, Pelliccioli GP, Calabresi P, Sarchielli P. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J Neurol Neurosurg Psychiatr 2008 11;79(1468-330; 0022-3050; 11):1224-9.   Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS. Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 2009 12/15;287(1878-5883; 0022-510; 1-2):212-5. Sativex (delta-9-tetrahydrocannabinol (THC) and cannabinol (CBD)) [product monograph]. Cambridge (United Kingdom): GW Pharma Ltd; 2019.  
Next Article
Migraines and Medicinal Cannabis
Migraines are debilitating headaches that affect millions of people worldwide. These intense headaches often come with a range of symptoms, including severe pain, nausea, and sensitivity to light and sound. For many migraine sufferers, finding effective treatments can be challenging. However, an increasing body of research suggests that medicinal cannabis may hold promise in alleviated the symptoms of migraines. Migraine Awareness Month, observed annually in June, serves as a critical opportunity to shed light on the impact of migraines and raise awareness. Understanding Migraines and Conventional Treatments Migraines are complex neurological disorders characterized by recurring headaches that can last for hours or even days. They can significantly impact a person’s quality of life, productivity, and overall well-being. Conventional treatments for migraines often involve over-the-counter pain medications, prescription drugs, lifestyle modifications, and avoidance of triggers. However, these approaches may not always provide satisfactory relief or can have adverse side effects. Cannabinoids and Migraine Relief The cannabis plant contains over 100 cannabinoids, with two main ones THC and CBD. Both THC and CBD have shown potential in addressing migraines, although their mechanisms of action differ. • THC: Tetrahydrocannabinol, the intoxicating/psychotropic component of cannabis, has been found to have pain-relieving properties. It can potentially help alleviate migraine-related pain by interacting with cannabinoid receptors in the brain and central nervous system. • CBD: Cannabidiol, a non-intoxicating cannabinoid, is known for its potential analgesic and anti-inflammatory properties. It may offer relief from migraines by modulating pain perception, reducing inflammation, and promoting relaxation. CBD is also believed to have anti-nausea effects, which can be beneficial for migraine sufferers who experience nausea and vomiting during attacks. • Balanced CBD:THC Effects: Some studies suggest that the combination of THC and CBD may have a synergistic effect, potentially enhancing the therapeutic benefits for migraine relief. This combination may offer a balance between pain reduction and minimizing any psychotropic side effects. View Product: Prime CBD View Product: Mango Haze Considerations and Precautions While cannabis shows promise in managing migraines, it is crucial to consult with a knowledgeable healthcare professional before considering medical cannabis for migraines. They can provide guidance on dosage, product selection, potential drug interactions, and ensure it is safe with your overall health condition. • Methods of consumption: THC and CBD have different effects depending on whether they are used to treat acute migraine attacks, reduce migraine frequency, or both. Inhalation of dried cannabis with a vaporization device has a fast-acting effect that usually begins to take effect in 3–10 minutes and lasts for 2–4 hours. Due to its fast onset of action, patients report using this method for acute migraine attacks. Oral ingestion of cannabis oil or softgels take longer to work but typically last for 8-12 hours. Patients report using this method to avoid migraines and to reduce their frequency and intensity. • Product selection: Different cannabis cultivars and products may have varying levels of cannabinoids and terpenes, which can influence their effects. Cultivars and products higher in CBD and lower in THC may be more suitable for individuals seeking migraine relief without significant psychotropic effects. • Individual responses: The effects of medicinal cannabis can vary from person to person. It is important to start with low doses and gradually titrate to find the optimal dosage that provides relief while minimizing any unwanted side effects. While there is potential for cannabis as a migraine treatment, more research is required to determine its efficacy, safety, and best application. Please consult with your healthcare practitioner if you're thinking about trying medicinal cannabis as a migraine alternative treatment. Need help getting a medicinal cannabis treatment plan for migraines? Book An Appointment References: Bell, A. D., MacCallum, C. A., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Jagpaul Kaur Deol, Lauren de Freitas, Michelle St Pierre, Belle-Isle, L., Gagnon, M., Bevan, S., Sanchez, T., Arlt, S., Monahan-Ellison, M., O’Hara, J., Boivin, M., & Costiniuk, C. T. (2023). Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. https://doi.org/10.1089/can.2021.0156 Rhyne, D. N., Anderson, S. L., Gedde, M., & Borgelt, L. M. (2016). Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. Pharmacotherapy, 36(5), 505–510. https://doi.org/10.1002/phar.1673 Russo, E. B. (2016). Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research, 1(1), 154–165. https://doi.org/10.1089/can.2016.0009

Loading